ImmuneOnco to Present at 2021 BIO Digital
Shanghai, China, June 10, 2021 – ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. announced today that it was selected to present at 2021 BIO Digital, the premier biotech event. BIO Digital is scheduled at June 10-11 & 14-18, 2021.
Dr. Kathy Yu, the VP of the company, who is responsible for BD, will present ImmuneOnco’s pipeline of proprietary platform-based product candidates targeting a broad range of indications in cancer, including:
(1) IMM01: SIRPα-IgG1FC fusion protein, monospecific anti-CD47 (Phase Ib)
(2) IMM0306: bispecific antibody-trap（mAb-Trap）, anti CD47xCD20 (Phase I in China and US)
(3) IMM2902: bispecific antibody-trap (mAb-Trap), anti CD47x HER2 (IND filing accepted by NMPA and IND filing to FDA is expected for July 2021)
The presentation will be available to registered attendees at 9 am ET June 10. Attendees at BIO Digital will be able to view ImmuneOnco’s Company Presentation before live meetings in the BIO One-on-One Partnering™ system begin on June 14.
Founded in June 2015 in the Zhangjiang Hi-Tech Park of the China (Shanghai) Pilot Free Trade Zone, ImmuneOnco focuses on development and research of anti-tumor immunotherapy products, including bispecific antibody-traps (mAb-Traps), novel recombinant proteins, and target-activated NK cell therapy.These compounds of ours aim to activate patients’ own immune system to exert anti-tumor effects, and ultimately inhibit endless growth of tumor cells and reverse malignant symptoms, so that patients can gradually return to being healthy. Currently, several new anti-tumor products of ours are in clinical development stage. ImmuneOnco is recognized by authorities as one of the ‘Top 50 Start-up Enterprises with the Most Investment Potential in Shanghai’ in 2016, the "Excellent Enterprise" in the 2017 China Innovation and Entrepreneurship Competition, and one of the winnersof the "Enterprise Excellence Award" of Shanghai Science and Technology Entrepreneurship in 2017.
BIO is the world's largest advocacy organization representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world.
For further cooperation, please contact
Address: Room 502, 1043 HaLei Road, Pudong New Area, Shanghai, China
Building 7, Lane 908, Ziping Road, Pudong New Area, Shanghai, China
Tel. + 86 21 5835 6573